TriSalus boosts CFO pay and grants options

TriSalus Life Sciences, Inc. increased annual compensation for its Chief Financial Officer, David Patience, as approved by the Compensation Committee.

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. increased annual compensation for its Chief Financial Officer, David Patience, as approved by the Compensation Committee. His annual base salary rose from $450,000 under his May 27, 2025 employment agreement to $550,000, effective immediately.

In addition, the Compensation Committee granted Mr. Patience stock options to purchase 249,899 shares of common stock at an exercise price of $5.11 per share. These options vest only if the company achieves or exceeds $75 million of revenue over any twelve consecutive calendar month period ending on or before December 31, 2027, tying his equity incentive to a specific revenue performance goal.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive compensation change did TriSalus Life Sciences (TLSI) approve?

TriSalus Life Sciences approved a higher base salary for its Chief Financial Officer. David Patience’s annual base pay increased from $450,000 to $550,000, effective immediately, reflecting updated compensation terms relative to his May 27, 2025 executive employment agreement.

How many stock options were granted to the TriSalus (TLSI) CFO?

The CFO, David Patience, received stock options to purchase 249,899 shares of TriSalus common stock. These options are an equity incentive tied to future performance and are exercisable at a specified per-share price if vesting conditions are satisfied.

What is the exercise price of the new TriSalus (TLSI) CFO stock options?

The stock options granted to the TriSalus CFO carry an exercise price of $5.11 per share. This means he can buy company shares at that fixed price if the options vest under the defined revenue-based performance condition.

What revenue target must TriSalus (TLSI) meet for the CFO options to vest?

The options vest only if TriSalus achieves or exceeds $75 million of revenue over any twelve consecutive calendar month period. That performance window must end on or before December 31, 2027, directly linking vesting to a specific revenue milestone.

When did TriSalus (TLSI) approve the CFO compensation increase and option grant?

The Compensation Committee approved the CFO’s salary increase on August 25, 2025. It then approved the stock option grant on August 28, 2025, establishing both cash and equity components to his updated compensation package on closely spaced dates.

Which executive at TriSalus (TLSI) is affected by this compensation update?

The changes affect David Patience, Chief Financial Officer of TriSalus Life Sciences. He received both a higher annual base salary and a performance-based stock option grant, aligning his compensation more closely with the company’s future revenue achievements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/29/2025 - 04:15 PM EDT Learn about SEC filing dates

0001826667FALSE00018266672025-08-252025-08-250001826667us-gaap:CommonStockMember2025-08-252025-08-250001826667us-gaap:WarrantMember2025-08-252025-08-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 25, 2025

TRISALUS LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-39813			85-3009869
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification No.)
6272 W 91st Ave, Westminster, Colorado						80031
(Address of principal executive office)						(Zip Code)

(888) 321-5212

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
o			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $0.0001 par value			TLSI			Nasdaq Global Market
Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per share			TLSIW			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 25, 2025, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of TriSalus Life Sciences, Inc. (the “Company”), approved an increase in the annual compensation of Mr. David Patience, the Company’s Chief Financial Officer, from the he $450,000 annual base salary indicated in his Executive Employment Agreement dated May 27, 2025 to $550,000, effective immediately.

In addition, on August 28, 2025, the Compensation Committee approved the granting of stock options to purchase 249,899 shares of common stock to Mr. Patience, exercisable at $5.11 per share. The options vest upon the Company achieving or exceeding $75 million of revenue over any twelve (12) consecutive calendar month period period ending on or before December 31, 2027.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 29, 2025			TriSalus Life Sciences, Inc.
			By:			/s/ Mary Szela
						Name:			Mary Szela
						Title:			Chief Executive Officer